Valuation: China Medical System Holdings Limited

Capitalization 30.27B 33.88B 4.34B 3.74B 3.49B 3.25B 6.04B 394B 6.5B 40.1B 15.81B 188B 16.29B 15.95B 686B P/E ratio 2025 *
18x
P/E ratio 2026 * 15.4x
Enterprise value 27.45B 30.72B 3.94B 3.4B 3.16B 2.94B 5.48B 357B 5.9B 36.37B 14.34B 170B 14.77B 14.47B 623B EV / Sales 2025 *
3.31x
EV / Sales 2026 * 2.83x
Free-Float
49.43%
Yield 2025 *
2.92%
Yield 2026 * 3.35%
More valuation ratios * Estimated data
Dynamic Chart
12-11 China Medical System announces NDA of class 1 innovative drug Y-3 for injection accepted by China's NMPA RE
12-11 China Medical System Holdings Limited Announces New Drug Application of Class 1 Innovative Drug Y-3 for Injection for Acute Ischemic Stroke Accepted in China CI
12-11 China Medical System's Brain Cytoprotectant Application Accepted in China MT
27/10/25 China Medical System signed a distribution agreement for ophthalmic drugs Lucentis and Beovu RE
27/10/25 China Medical System Holdings Limited Through its Subsidiary CMS VISION INTERNATIONAL MANAGEMENT LIMITED Enters into Distribution Agreement with Novartis Pharma Services AG for Ranibizumab Injection and Brolucizumab Injection CI
27/10/25 China Medical System Enters Distribution Contract with Novartis Pharma Services for Ophthalmic Drugs MT
27/10/25 China Medical System says entered distribution agreement with Novartis Pharma Services AG RE
30/09/25 China Medical System announces Mg-K10 drug trial approval by NMPA RE
30/09/25 China Medical System Holdings Limited Announces Approval of Drug Clinical Trials for Additional Chronic Obstructive Pulmonary Disease Indication CI
30/09/25 Ruizheng Gene Co., Ltd. announced that it has received $75 million in funding from China Medical System Holdings Limited, Tibet Rhodiola Pharmaceutical Holding Co. CI
29/09/25 China Medical System Unit Receives Regulatory Nod to Conduct Phase 3 Trial of Skin Drug MT
26/09/25 China Medical System Unit Gets Positive Results from Atopic Dermatitis Drug Study MT
26/09/25 China Medical System Holdings Limited Announces Approval of Drug Clinical Trials for Uterine Fibroids Indication of Innovative Drug GnRH Receptor Antagonist CMS-D002 CI
More news
1 day-0.92%
1 week+0.36%
Current month+8.68%
1 month+5.73%
3 months+2.49%
6 months+7.19%
Current year+8.68%
More quotes
1 week 13.82
Extreme 13.82
14.45
1 month 12.74
Extreme 12.74
14.45
Current year 12.89
Extreme 12.89
14.45
1 year 6.71
Extreme 6.71
15.63
3 years 6.23
Extreme 6.23
15.86
5 years 6.23
Extreme 6.23
22.8
10 years 6.14
Extreme 6.14
22.8
More quotes
Manager TitleAgeSince
Chief Executive Officer 61 31/03/2020
Director of Finance/CFO 55 -
Chief Tech/Sci/R&D Officer 66 01/01/2007
Director TitleAgeSince
Chairman 61 18/12/2006
Director/Board Member 55 18/12/2006
Director/Board Member 60 13/12/2017
More insiders
Change 5d. change 1-year change 3-years change Capi.($)
-0.92%+0.36%+100.86%+2.49% 4.39B
+0.53%-4.31%+39.06%+187.15% 925B
-0.41%+6.27%+50.83%+26.08% 529B
-0.31%-4.36%+25.09%+39.55% 383B
+0.93%+2.80%+31.21%+19.61% 368B
+0.19%-0.87%+31.97%+20.56% 291B
+0.98%+1.62%+27.62%+36.80% 274B
-1.93%-1.95%+8.73%-3.05% 275B
+6.49%+5.01%-35.72%-16.95% 252B
+0.12%+0.09%+22.86%+21.59% 178B
Average +0.57%+0.30%+30.25%+33.38% 347.91B
Weighted average by Cap. +0.56%+0.14%+28.42%+64.40%
See all sector performances

Financials

2025 *2026 *
Net sales 8.29B 9.28B 1.19B 1.03B 955M 889M 1.66B 108B 1.78B 10.98B 4.33B 51.49B 4.46B 4.37B 188B 9.63B 10.78B 1.38B 1.19B 1.11B 1.03B 1.92B 125B 2.07B 12.76B 5.03B 59.81B 5.18B 5.08B 218B
Net income 1.68B 1.88B 240M 207M 193M 180M 334M 21.81B 360M 2.22B 875M 10.41B 902M 883M 37.99B 1.94B 2.17B 278M 240M 223M 208M 387M 25.25B 416M 2.57B 1.01B 12.04B 1.04B 1.02B 43.97B
Net Debt -2.82B -3.16B -405M -349M -325M -302M -563M -36.71B -606M -3.74B -1.47B -17.51B -1.52B -1.49B -63.94B -3.04B -3.4B -436M -376M -350M -326M -606M -39.55B -652M -4.02B -1.59B -18.86B -1.63B -1.6B -68.88B
More financial data * Estimated data
Logo China Medical System Holdings Limited
China Medical System Holdings Ltd is an investment holding company principally engaged in the production of medicines, as well as marketing, promotion and sales of drugs. The Company's products include Plendil, Ursofalk, Augentropfen Stulln Mono Eye Drops, Hirudoid, Atopic Piel Series and Vmonalisa, among others. Its major marketed products cover the cardio-cerebrovascular, gastroenterology, ophthalmology, dermatology and medical aesthetic fields. The Company distributes its products within domestic market and to overseas markets.
Employees
6,095
More about the company
Date Price Change Volume
16/01/26 14.02 $ -0.92% 2,013,000
15/01/26 14.15 $ +0.86% 2,544,000
14/01/26 14.03 $ -0.99% 3,298,000
13/01/26 14.17 $ -0.07% 4,283,701
12/01/26 14.18 $ -0.14% 3,794,652

Delayed Quote Hong Kong S.E., January 16, 2026 at 04:08 pm

More quotes
Trader
Investor
Global
Quality
ESG MSCI
AA
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
12.53CNY
Average target price
15.28CNY
Spread / Average Target
+22.02%
Consensus

Quarterly revenue - Rate of surprise